Setup News Ticker
Searching for 'Buy Stocks'. (Return)

Yahoo BusinessMar 31, 2020
Trump and Putin Are All Talk on Oil Price Plunge
Dividends are periodic payments a company makes to shareholders out of the profits it generates, provided it has a dividend policy. They assure a stable, steady stream of returns to shareholders -- unlike capital gains, which are subject to fluctuations triggered by company-specific and extraneous factors.The coronavirus pandemic and its impact on companies has put this steady stream of income at risk.Unable to cough up cash to meet dividend payments at a time when businesses are reeling to keep operations going, several companies have announced suspension of dividends or pauses of stock buybacks.Dividends In Value Vs. Growth Investing To compare the returns of a stock, a metric called dividend yield is used. Dividend yield is the amount of dividend paid by a company for a year, divided by its current stock price and expressed in percentage terms.Value stocks -- stocks that are trading at a lower price relative to their fundamentals -- invariably have a higher dividend yield. Most value stocks belong to mature companies that can afford to pay dividends due to their strong cash flows.Unlike value stocks, growth stocks are mostly up-and-coming companies that do not have the luxury of steady cash flows to fund dividend payouts. Even if their cash flows support payouts, they would often rather invest in growth opportunities than on dividends. Investors in these companies rely on capital gains or share price appreciation to realize returns.Due to the high P/E ratios of these companies, their dividend payouts tend to be lower.See also: 8 Best Investment Strategies During A Recession D

MarketWatch MarketPulseMar 31, 2020
Amarin's stock plummets on heavy volume after court rules in favor of makers of generic Vascepa
Shares of Amarin Corp. PLC took a 69% dive on heavy volume in premarket trading Tuesday, after drug maker announced a disappointing court ruling in its patent litigation against two generic companies regarding Vascepa, its Food and Drug Administration-approved treatment of cardiovascular disease. Trading volume ballooned to over 10 million shares ahead of the open, which is already more than the full-day average of 9.6 million shares. Amarin said late Monday that the U.S. Distric Court for the Distric of Nevada ruled in favor of the generic companies. "Amarin strongly disagrees with the ruling and will vigorously pursue all available remedies, including an appeal of the Court's decision and a preliminary injunction pending appeal to, if an ANDA is approved by FDA, prevent launch of generic versions of VASCEPA in the United States," said Cief Executive John Thero. Stifel Nicolaus analyst Derek Archila reiterated his hold rating but slashed his stock price target to $8 from $24, saying he believes the court ruling will be difficult to overturn on appeal. "The negative IP ruling is a serious blow for [Amarin], and we would not be buying shares here given the uncertainty the decision has created around the future of Vascepa sales and, more importantly, [Amarin's] near-to-medium term cash runway," Arichila wrote in a note to clients. Through Monday, Amarin's stock had declined 36.7% over the past three months while the S&P 500 had lost 18.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

coronavirusamid live Pandemic Market cases
Stockmarket coronavirus quarter live futures
COVID-19Johnson Pandemic vaccine cases Coronavirus
marketStock Coronavirus Dow futures live
Stockscoronavirus quarter Chinese end higher
ChinaVirus coronavirus factory markets Asia
amidCoronavirus workers Oil pandemic outbreak
FilerINC 8-K 6-K CORP Funds
Oil18-year lows Russia talks rises
Yorkcoronavirus Times Post City live

Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money Real Estate News Analysis Indicators
Enterprise Application News
Forbes Headlines
Forbes Social Media News - China, Economy & Trade - Financial Markets - Hedge Funds - Telecoms - US
Google Business News
Google Market News
HBS Working Knowledge
INSEAD Knowledge
International Tax Review
L.S. Starrett News
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money Updates: News Digest
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC